SCYX 8-K SEC Filing Analysis

Latest settled — T+5d

SCYX ▼ -2.17% at T+5d

NEUTRAL call ✗ call lost -2.17% · α vs SPY -3.25% · entry $5.45 → $5.33

Next anchor: T+20d in 10d

Currently $4.23 · -22.36% from $5.45 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

+2.92%

call +2.92% · α +2.91%

$5.61

settled 18d ago

T+5d

-2.17%

call -2.17% · α -3.25%

$5.33

settled 12d ago

T+20d

—

call — · α —

—

in 10d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

SCYNEXIS shareholders approved a reverse stock split at a special meeting on May 19, 2026, with 44.8M votes for and 6.7M against. The Board subsequently set the ratio at 1-for-8, effective May 29, 2026, reducing authorized shares from 150M to 18.75M. This is a routine capital structure adjustment to maintain Nasdaq listing compliance, with no fundamental business impact.

Actionable Insight

The reverse split is a mechanical adjustment to maintain Nasdaq listing compliance and does not change the company's fundamental value. Monitor for any subsequent equity offering or business development updates that could affect the post-split share price.

Key Facts

Shareholders approved reverse stock split at a ratio between 1:5 and 1:10 at a special meeting on May 19, 2026
Board set the specific ratio at 1-for-8 on May 19, 2026
Reverse stock split effective May 29, 2026; split-adjusted trading begins June 1, 2026
Authorized shares reduced from 150,000,000 to 18,750,000
No fractional shares will be issued; cash paid in lieu of fractional shares
Ticker symbol SCYX unchanged; new CUSIP is 811292 309

Financial Impact

No direct financial impact; authorized shares reduced from 150M to 18.75M via 1:8 reverse split. Proportional ownership unchanged except for fractional share cash-outs.

shares outstandingauthorized shares

Risk Factors

Post-split stock may face selling pressure from retail holders cashing out fractional shares
Reverse splits are often viewed negatively by the market as a sign of distress, though this is a routine compliance action
Reduced share count increases volatility on a per-share basis

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

89% bullish (9 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001178253-26-000014
Document: 0001178253-26-000014-index-headers.html	0001178253-26-000014
Document: 0001178253-26-000014-index.html	0001178253-26-000014
Document: 0001178253-26-000014.txt	0001178253-26-000014

5 reports for SCYX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +12.34%Mar 4, 2026

Filters

Reports for SCYX — sortable, filterable
	Type				Now
May 22, 2026 21d ago	8-K NEUTRAL ★ 4/10	$5.45 $5.33	▼ −2.17%	▼ −3.25%	$4.23 (−22.36%)
May 11, 2026 4w ago	Press Release BEARISH ★ 7/10	$0.7800 $0.6850	▲ +12.18%	▲ +12.26%	$4.23 (−442.31%)
Apr 20, 2026 7w ago	8-K NEUTRAL ★ 3/10	$1.06 $0.9860	▼ −6.98%	▼ −8.06%	$4.23 (+299.06%)
Mar 31, 2026 10w ago	Press Release BULLISH ★ 7/10	$0.9170 $0.9960	▲ +8.62%	▲ +4.67%	$4.23 (+361.29%)
Mar 4, 2026 14w ago	Press Release BULLISH ★ 8/10	$6.34 $7.12	▲ +12.34%	▲ +14.58%	$4.23 (−33.28%)

US Market Status

Market Closed — Opens Mon (48h 45m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access